MHMartin Henzel

Martin Henzel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Henzel has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients

    by Emmanouil Fokas, Martin Henzel, Klaus Hamm, Steffen Grund, Rita Engenhart-Cabillic

    We investigated the impact of human epidermal growth factor receptor 2 (HER2) and prognostic factors in the outcome of patients with breast cancer that developed brain metastases. . The data from 94 patients who received multidisciplinary therapy from 2001 to 2007 were retrospectively reviewed. Patients were assigned according to their HER2 status, and overall survival and time to brain metastases recurrence/progression were evaluated. The prognostic value of age, presence of extracerebral metastases, recursive partitioning analysis class, hormone therapy, systemic therapy and trastuzumab was assessed. The median overall survival and time to brain disease progression were 7.1 and 6.5 months, respectively. HER2 positivity (P = 0.006), treatment with trastuzumab (P = 0.025), chemotherapy (P = 0.011) and recursive partitioning analysis class I-II (P <0.001) were associated with prolonged survival on univariate analysis. On multivariate analysis, only recursive partitioning analysis class I-II (P <0.001) and triple-negative disease (P = 0.04) remained significant for overall survival, whereas time to brain metastases progression was only associated with recursive partitioning analysis class I-II (P = 0.001). The time from the diagnosis of primary disease to brain metastasis was slightly shorter in the HER2+ patients than in HER2- patients (36 vs 39 months). Intensified local treatment of brain metastasis incorporating whole-brain radiotherapy and/or radiosurgery and neurosurgery did not affect survival. Patients with triple-negative disease presented a significantly lower survival than the rest of the cohort (4 vs 8 months; P = 0.012). Recursive partitioning analysis class I-II was found to be the strongest independent predictive factor. Treatment with trastuzumab in HER2+ patients appeared to improve overall survival, probably due to the better control of systemic metastatic disease, but did not maintain significance in multivariate analysis. The dismal prognosis of patients with triple-negative breast cancer highlights the need to develop novel therapies to improve the poor survival.


  • Comparison of Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy of Acoustic Neurinomas According to 3-D Tumor Volume Shrinkage and Quality of Life

    by Martin Henzel, Klaus Hamm, Helmut Sitter, Markus W. Gross, Gunnar Surber, Gabriele Kleinert, Rita Engenhart-Cabillic

    Stereotactic radiosurgery (SRS) and also fractionated stereotactic radiotherapy (SRT) offer high local control (LC) rates (> 90%). This study aimed to evaluate three-dimensional (3-D) tumor volume (TV) shrinkage and to assess quality of life (QoL) after SRS/SRT.


  • Fractionated Stereotactic Radiotherapy of Glomus Jugulare Tumors

    by Martin Henzel, Klaus Hamm, Markus W. Gross, Gunnar Surber, Gabriele Kleinert, Thomas Failing, Helmut Sitter, Gerd Strassmann, Rita Engenhart-Cabillic

    For glomus jugulare tumors, the goal of treatment is microsurgical excision. To minimize postoperative neurologic deficits, stereotactic radiosurgery (SRS) was performed as an alternative treatment option. Stereotactic fractionated radiotherapy (SRT) could be a further alternative. This study aims at the assessment of local control, side effects, and quality of life (QoL). Between 1999–2005, 17 patients were treated with SRT. 11/17 underwent previous operations. 6/17 received primary SRT. Treatment was delivered by a linear accelerator with 6-MV photons. Median cumulative dose was 57.0 Gy. Local control, radiologic regression, toxicity, and symptomatology were evaluated half-yearly by clinical examination and MRI scans. QoL was assessed by Short Form-36 (SF-36). Median follow-up was 40 months. Freedom from progression and overall survival for 5 years were 100% and 93.8%. Radiologic regression was seen in 5/16 cases, 11/16 patients were stable. Median tumor shrinkage was 17.9% (p = 0.14). Severe acute toxicity (grade 3–4) or any late toxicity was never seen. Main symptoms improved in 9/16 patients, 7/16 were stable. QoL was not affected in patients receiving primary SRT. SRT offers an additional treatment option of high efficacy with less side effects, especially in cases of large tumors, morbidity, or recurrences after incomplete resections. Standardtherapie von Glomus-jugulare-Tumoren ist die mikrochirurgische Resektion. Zur Vermeidung postoperativer neurologischer Defizite wurde die stereotaktische Radiochirurgie (SRS) als Behandlungsalternative etabliert. Die stereotaktisch-fraktionierte Radiotherapie (SRT) könnte eine weitere Alternative darstellen. Ziel dieser Studie ist die Evaluation der lokalen Kontrolle, Nebenwirkungen und Lebensqualität. Zwischen 1999 und 2005 wurden 17 Patienten stereotaktisch-fraktioniert bestrahlt. 11/17 waren voroperiert, 6/17 wurden primär bestrahlt. Die Bestrahlung erfolgte mit einem Linearbeschleuniger mit 6-MV-Photonen. Die mediane Gesamtdosis betrug 57,0 Gy. Die lokale Kontrolle, radiologische Regression, Toxizität und Symptomatologie wurden halbjährlich mittels klinischer Untersuchungen und MRT-Kontrollen erfasst. Die Lebensqualität wurde mit dem Fragebogen Short Form-36 (SF-36) evaluiert. Die mediane Nachbeobachtungszeit lag bei 40 Monaten. Das 5-Jahres-Gesamtüberleben betrug 93,8%, das progressionsfreie Überleben 100%. Radiologische Regression trat in 5/16 Fällen auf, in 11/16 war der Tumor kontrolliert. Die mediane Tumorschrumpfung betrug 17,9% (p = 0,14). Schwere Akuttoxizität (CTC Grad 3–4) oder jegliche Spättoxizität wurde nicht beobachtet. In 9/16 Fällen konnten die Hauptsymptome gebessert werden, in 7/16 waren sie stabil. Die Lebensqualität primär mit SRT behandelter Patienten war nicht beeinträchtigt. Die SRT bietet eine zusätzliche Option von hoher Effektivität mit geringer Nebenwirkungswahrscheinlichkeit. Das gilt insbesondere für große Tumoren, für morbide Patienten und im Rezidivfall nach inkompletter Resektion.


  • Open Access

    SIGNIFICANT TUMOR VOLUME REDUCTION OF MENINGIOMAS AFTER STEREOTACTIC RADIOTHERAPY

    by Martin Henzel, Markus W. Gross, Klaus Hamm, Gunnar Surber, Gabriele Kleinert, Thomas Failing, Gerd Strassmann, Rita Engenhart-Cabillic

    OBJECTIVE. Stereotactic radiosurgery (SRS) is well established in the treatment of cranial base meningiomas. Fractionated stereotactic radiotherapy (SR


  • Stereotactic Radiotherapy of Meningiomas

    by Martin Henzel, Markus W. Gross, Klaus Hamm, Gunnar Surber, Gabriele Kleinert, Thomas Failing, Gerd Strassmann, Rita Engenhart-Cabillic

    Background and Purpose: Stereotactic radiosurgery (SRS) is well established in the treatment of skull base meningiomas, but this therapy approach is limited to small tumors only. The fractionated stereotactic radiotherapy (SRT) offers an alternative treatment option. This study aims at local control, symptomatology, and toxicity. Patients and Methods: Between 1997–2003, 224 patients were treated with SRT (n = 183), hypofractionated SRT (n = 30), and SRS (n = 11). 95/224 were treated with SRT/SRS alone. 129/224 patients underwent previous operations. Freedom from progression and overall survival, toxicity, and symptomatology were evaluated systematically. Additionally, tumor volume (TV) shrinkage was analyzed three-dimensionally within the planning system. Results: The median follow-up was 36 months (range, 12–100 months). Overall survival and freedom from progression for 5 years were 92.9% and 96.9%. Quantitative TV reduction was 26.2% and 30.3% 12 and 18 months after SRT/SRS (p < 0.0001). 95.9% of the patients improved their symptoms or were stable. Clinically significant acute toxicity (CTC III°) was rarely seen (2.5%). Clinically significant late morbidity (III°–IV°) or new cranial nerve palsies did not occur. Conclusion: SRT offers an additional treatment option of high efficacy with only few side effects. In the case of large tumor size (> 4 ml) and adjacent critical structures (< 2 mm), SRT is highly recommended.


  • Tumor Volume Shrinkage after SRT

    by Rita Engenhart-Cabillic, Martin Henzel, M. Gross, K. Hamm, G. Surber, G. Kleinert, G. Strassmann

    Introduction: Fractionated stereotactic radiotherapy (SRT) is well established in the treatment of skull base meningiomas. Local tumor control is excellent (overall survival and the progression-free survival rates for 5 years: 92.9% and 96.9%, respectively). During follow-up 1/3 of the patients developed a radiological regression. We examined 94 patients prospectively in both departments to analyze quantitatively the tumor volume (TV) shrinkage. Material and Methods: Ninety-four patients (78 female, 16 male) suffering from a WHG I meningioma were examined under equal conditions (i.e., same technique and MRI scanner) before 6, 12, 18, and 24 months after SRT. Fat-saturated axial T1-weighted contrast-enhanced magnetic resonance imaging (MRI) scans with a 3-mm slice thickness were used. After image fusion TV was drawn in each slice for analyzing TV shrinkage three-dimensionally by the planning system. Results: Initially the mean TV was 13.4 mL (median: 8.5 mL). A decreasing mean TV shrinkage leading to a steady state was seen after SRT: 17.6% after 6 months (p < 0.0001), 24.7% after 12 months (p < 0.0001), 29.1% after 18 months (p < 0.0001), and 29.1% after 24 months (p = 0.05). Age at start of treatment showed a less intense TV shrinkage with increasing age (p < 0.05). Patients younger/older than 55 years revealed a significant mean shrinkage of 29.7%/20.0%, respectively (p < 0.05). A tendency for a correlation between initial TV and mean shrinkage was observed: smaller TV (< 8.5 mL): 26.5%, larger TV (> 8.5 mL): 23.7% (p = 0.11). There was no correlation between TV shrinkage versus improvement of the symptoms, versus prescribed dosis versus histology. Conclusions: SRT is a very effective method for the treatment of skull base meningiomas. An approximately 30% TV shrinkage is seen 2 years after irradiation. Smaller TV and younger age are factors determining extent of TV shrinkage. Prescribed dosis or histology do not affect TV shrinkage.